Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Mallon

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancerJack Cuzick, Mitch Dowsett, Silvia Pineda, et al.
Cancer Medicine|December 11, 2024
Elucidation of Dysregulated Pathways Associated With Hypoxia in Oestrogen Receptor-Negative Breast CancerSuad A K Shamis, Jean Quinn, Sara Al-Badran, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2022
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast CancerKeying Xu, Jane Bayani, Elizabeth Mallon, et al.
Breast Cancer Research : BCR|September 12, 2022
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC studyElena Lopez-Knowles, Simone Detre, Margaret Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 TrialOtto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trialsBernhard C Pestalozzi, David Zahrieh, Elizabeth Mallon, et al.
The Lancet. Oncology|November 5, 2020
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trialIan Smith, John Robertson, Lucy Kilburn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2008
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialMitch Dowsett, Craig Allred, Jill Knox, et al.
Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancerJack Cuzick, Mitch Dowsett, Silvia Pineda, et al.
Cancer Medicine|December 11, 2024
Elucidation of Dysregulated Pathways Associated With Hypoxia in Oestrogen Receptor-Negative Breast CancerSuad A K Shamis, Jean Quinn, Sara Al-Badran, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2022
Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast CancerKeying Xu, Jane Bayani, Elizabeth Mallon, et al.
Breast Cancer Research : BCR|September 12, 2022
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC studyElena Lopez-Knowles, Simone Detre, Margaret Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 TrialOtto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trialsBernhard C Pestalozzi, David Zahrieh, Elizabeth Mallon, et al.
The Lancet. Oncology|November 5, 2020
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trialIan Smith, John Robertson, Lucy Kilburn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2008
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialMitch Dowsett, Craig Allred, Jill Knox, et al.
Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.
Pageof 4